MMD INCREASES STAKE IN KODAMA
US company Marion Merrell Dow is increasing its stake in Japanese pharmaceutical concern Kodama, through its Japanese subsidiary. MMD KK acquired a 20% stake in the company earlier this year (Marketletter March 8), and is now increasing this stake to 38%, with plans to increase its ownership of Kodama to over 50% early next year.
"This action allows us to participate in the Japanese market more fully by benefiting from Kodama's long experience in both sales and development. We are confident that the early strengthening of this relationship will lead to even more efficient product development, new products and sales promotion activities," said Michael Aylott, president of MMD in Japan.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze